Trials / No Longer Available
No Longer AvailableNCT03501940
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Andrei Iagaru · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such as fluorine F 18 DCFPyL PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate fluorine F 18 DCFPyL (18F-DCFPyL) PET/CT for detection of recurrent prostate cancer after initial therapy in patients with elevated prostate-specific antigen (PSA). OUTLINE: Participants receive fluorine F 18 DCFPyL intravenously (IV). After 60-120 minutes, participants undergo whole body PET/CT. Immediately after the first scan, participants may undergo a second PET/CT without receiving fluorine F 18 DCFPyL. After completion of study, participants are followed up at 24-72 hours.
Conditions
- Prostate Adenocarcinoma
- PSA Level Greater Than 0.2
- PSA Level Greater Than or Equal to Two
- PSA Progression
- Recurrent Prostate Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Computed Tomography | Undergo 18F-DCFPyL PET/CT |
| RADIATION | Fluorine F 18 DCFPyL | Given IV |
| OTHER | Laboratory Biomarker Analysis | Correlative studies |
| PROCEDURE | Positron Emission Tomography | Undergo 18F-DCFPyL PET/CT |
Timeline
- First posted
- 2018-04-18
- Last updated
- 2022-01-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03501940. Inclusion in this directory is not an endorsement.